This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Express Scripts-Medco Deal: Impact on Walgreen Stock

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK ( Trefis) -- Walgreen (WAG) announced its second-quarter results last week. The earnings beat analyst expectations even though the number of prescriptions filled at comparable stores fell by 8% to 9% as a result of the drug retailer walking out of Express Scripts network this year. What is generating more curiosity is the future of Walgreen's business with Medco now that the FTC has approved the Express Scripts-Medco deal.

The company's management indicated in its latest earnings call that it hopes to maintain its relationship and contracts with Medco. Others speculate that Walgreen may hammer out a fresh deal with Express Scripts soon. This certainly bodes well for WAG stock which currently trades at $35, and has lost almost a quarter of its value since its impasse with Express Scripts in June 2011. Walgreen competes with CVS Caremark (CVS) and Rite Aid (RAD).

View our analysis for Walgreen .

Walgreen and Express Scripts parted ways last year after failing to renew contract worth $5 billion over disagreement on reimbursement rates. As the FTC has approved the merger between Express Scripts and Medco Health Solutions, there are concerns about the implications for Walgreen and the future of its prescription business from Medco (Walgreen filled 125 million prescriptions for Medco clients in 2011). There were also talks of Walgreen considering buying out Rite Aid.

The recent buzz is that Walgreen could try to enter a new contract with Express Scripts as the management appeared positive about doing business with Medco. In fact, UBS expects the deal as soon as April or May and has even raised its price target for Walgreen to $39. This would certainly be in the interests of both Walgreen and Express-Medco.

We currently value Walgreen with a $35 Trefis price estimate of its stock, which is 3% ahead of the current market price.

Click here to find out how a company's products impact its stock price at Trefis

Like our charts? Embed them in your own posts using the Trefis Wordpress Plugin.
This commentary comes from an independent investor or market observer as part of TheStreet guest contributor program. The views expressed are those of the author and do not necessarily represent the views of TheStreet or its management.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs